Prevention and Treatment of Regimen-Related Mucosal Toxicity
Pp. 588-600 (13)
DOI:
10.2174/978160805161811001010588
Author(s):
Joanne M. Bowen
Department of Medical Oncology, Royal Adelaide Hospital, and School of Medicine, University of Adelaide, Adelaide, South Australia, 5000, Australia, Australia
Affiliation:
Abstract
Current standard treatments for cancer are associated with major doselimiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and anti-inflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however, rational targeting of intervention strategies to critical mechanisms will lead to further progress.
Keywords:
Mucosal injury, mucositis, chemotherapy, radiotherapy, inflammation, apoptosis, growth factor, intestine, oral